On April 3, 2026, R&D World reported — citing Newcomer and The Information — that Anthropic had acquired Coefficient Bio in an all-stock deal worth just over $400 million, with OncoDaily following on April 4. The target: a New York startup founded in September 2025, a team of fewer than ten, building biology-native AI tooling for drug research and development.
By 2026 standards the money is small; the direction is not. This is Anthropic’s first biotech acquisition, and it marks the frontier-lab contest shifting from general models toward who can absorb biology workflows into a product.
$400 Million for a Team Under Ten
The deal’s shape says a lot about the moment. All stock, just over $400 million — roughly 0.1% dilution against the $380 billion post-money valuation from Anthropic’s February Series G. Coefficient Bio was founded in September 2025; most of its staff came from Prescient Design, Genentech’s computational drug-discovery unit, and its main backer, the health-tech investor Dimension, held about half the company’s equity. Eight months old, nine people, $400 million. This is a capability acquisition — what’s being bought is the team and the workflows they built, not revenue.
The Founders and What They Built
Samuel Stanton (PhD, NYU, data science) worked on Cortex at Prescient Design, a modular deep-learning architecture for drug discovery, and co-authored Beignet, an open-source standard for molecular representation. Nathan C. Frey (PhD, Penn, materials science) won an ICLR 2024 Outstanding Paper award, is a 2026 Termeer Fellow, led a multidisciplinary group at Prescient on biological foundation models, and ran its NVIDIA collaboration.
Per The Information, Coefficient’s platform already let AI draft drug R&D plans, manage clinical regulatory strategy, and identify new drug opportunities. Both founders came out of Prescient Design, the Genentech unit built to apply machine learning to antibody design — precisely the domain depth a frontier lab cannot assemble quickly in-house. Stanton, announcing the deal, wrote: “We’re ushering biopharma into the Intelligence Age.”
Into Anthropic’s Life Sciences Group
The team joins Anthropic’s Health Care Life Sciences division, whose head, Eric Kauderer-Abrams, has stated the roadmap plainly: make Claude “hands down the best model for everything in biology.” The move doesn’t start from zero. Anthropic shipped Claude for Life Sciences in October 2025 with connectors to PubMed, Benchling, and ClinicalTrials.gov, and had previously acquired Bun and Vercept. Coefficient is its first biotech target — and, as OncoDaily notes, OpenAI’s plan for an automated researcher adds competitive urgency to the move. Read together, the pieces suggest what Anthropic is actually buying: the layer that turns a general-purpose model into a pharmaceutical co-worker, handling planning, regulatory memory, and candidate triage.
Why Pharma Talent Is Flowing to AI Labs
The backdrop is a reversal in where computational biologists go. Genentech cut at least 489 roles in 2025, and some of that talent moved into AI-native startups such as Xaira Therapeutics. NVIDIA and Eli Lilly announced a $1 billion AI drug-discovery lab partnership in January 2026. Capital is following the same line: Breakout Ventures closed a $114 million fund in March that explicitly targets the AI-biology convergence, and Dimension is reportedly raising a third fund of around $700 million.
What It Means for AI-Driven Biopharma
Three watch points. First, at more than $40 million per head, the deal buys workflows and domain data, not models — the moat in biology is process and data, not the next set of weights. Second, biotech developers should expect Claude-ecosystem tooling for drug R&D to accelerate: literature search, molecular representation, and regulatory strategy are all natural extensions of the Claude for Life Sciences base. There is a research-quality angle too: if Coefficient’s planning and regulatory tooling ships inside Claude, drug R&D plans become artifacts a model can draft and a human can audit — the same working pattern agentic coding tools established for software. Third, the vertical-integration race we flagged in our year-opening outlook is speeding up: pharma either builds AI capability in-house, or watches talent and tooling drain toward the frontier labs.
Sources
- Anthropic’s $400M Acquisition of Coefficient Bio Signals a Deeper Push Into Drug Discovery — R&D World
- Anthropic’s $400M Bold Bet on Coefficient Bio Signals a Critical Shift in AI Drug Discovery — OncoDaily
- Anthropic Acquires Coefficient Bio: AI in Drug Discovery — IntuitionLabs
AI-assisted summary compiled from the sources above, reviewed by a human before publishing.